Reckitt Benckiser Group plc (RBGLY)
- Previous Close
11.18 - Open
11.32 - Bid --
- Ask --
- Day's Range
11.28 - 11.49 - 52 Week Range
10.24 - 15.94 - Volume
601,810 - Avg. Volume
1,203,034 - Market Cap (intraday)
40.358B - Beta (5Y Monthly) 0.06
- PE Ratio (TTM)
19.81 - EPS (TTM)
0.58 - Earnings Date Jul 24, 2024 - Jul 29, 2024
- Forward Dividend & Yield 0.48 (4.21%)
- Ex-Dividend Date Apr 11, 2024
- 1y Target Est
12.80
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands. The company also offers home fragrances and devices; water softeners; home cleaning products; dish washes; toilet cleaners; disinfecting sprays wipes, laundry sanitisers, and others; sprays, baits, and plug-ins for pest control; stain removals; and fabric washing under the Air Wick, Calgon, Cillit Bang, Finish, Harpic, Lysol, Mortein, Vanish, and Woolite brands. In addition, it provides nutritious complementary foods and milk formulas for infant and young children under the Enfamil and Nutramigen brands. The company was founded in 1819 and is headquartered in Slough, the United Kingdom.
www.reckitt.com40,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: RBGLY
Performance Overview: RBGLY
Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RBGLY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RBGLY
Valuation Measures
Market Cap
39.81B
Enterprise Value
49.20B
Trailing P/E
19.90
Forward P/E
13.83
PEG Ratio (5yr expected)
1.62
Price/Sales (ttm)
2.22
Price/Book (mrq)
3.76
Enterprise Value/Revenue
2.65
Enterprise Value/EBITDA
12.21
Financial Highlights
Profitability and Income Statement
Profit Margin
11.25%
Return on Assets (ttm)
7.43%
Return on Equity (ttm)
18.36%
Revenue (ttm)
14.61B
Net Income Avi to Common (ttm)
1.63B
Diluted EPS (ttm)
0.58
Balance Sheet and Cash Flow
Total Cash (mrq)
1.39B
Total Debt/Equity (mrq)
100.80%
Levered Free Cash Flow (ttm)
2.27B